BIG
AMLX icon

Brooklyn Investment Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

Brooklyn Investment Group’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-42
Closed -$270 – 759
2025
Q2 		$270 Buy
+42
New +$204 ﹤0.01% 3164

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Brooklyn Investment Group's AMLX Position: Q3 2025 in Review

Brooklyn Investment Group sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2025, closing a stake of 42 shares — an estimated $270 sold.

Brooklyn Investment Group first reported a position in AMLX in Q2 2025 and held it in 1 quarter. The position peaked at $270 in Q2 2025. 169 funds tracked by Wall St. Rank hold AMLX as of Q3 2025.

  • Brooklyn Investment Group reported no remaining Amylyx Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Brooklyn Investment Group sold 42 Amylyx Pharmaceuticals shares in Q3 2025, an estimated $270.
  • Brooklyn Investment Group first reported a position in Amylyx Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Brooklyn Investment Group's Amylyx Pharmaceuticals position peaked at $270 in Q2 2025.
  • 169 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2025.

Based on Brooklyn Investment Group's 13F filing for Q3 2025, filed 14 Nov 2025.